Start RA treatment – Biologics or JAK-inhibitors?
Roberto Caporali, Sabino Germinario, Dorottya Kacsándi, Ernest Choy, Zoltán Szekanecz
Topics & Concepts
TofacitinibMedicineRheumatoid arthritisJanus kinaseJanus kinase inhibitorRuxolitinibAdverse effectBiosimilarIntensive care medicineInternal medicineMyelofibrosisCytokineBone marrowRheumatoid Arthritis Research and TherapiesChronic Lymphocytic Leukemia ResearchAutoimmune and Inflammatory Disorders Research